BiotechTube
Swedish Orphan Biovitrum

Swedish Orphan Biovitrum

SOBI.STApproved
1,000-2,000 employeessobi.com

Swedish Orphan Biovitrum AB (Sobi) is a publicly-traded Swedish specialty pharmaceutical company dedicated to rare diseases, hematology, immunology, and specialty care. With a market valuation of approximately $13.3 billion, Sobi has built a strong commercial portfolio including treatments for hemophilia, primary immunodeficiencies, and other rare conditions. The company combines in-house R&D capabilities with strategic partnerships and acquisitions to advance innovative therapies from development through commercialization.

Market Cap
$13.4B
+24.3% period
Pipeline
85
26 in Phase 3
Patents
20
granted
Publications
19
indexed

SOBI.ST · Stock Price

USD 360.00+70.40 (+24.31%)

Historical price data

AI Company Overview

Swedish Orphan Biovitrum AB (Sobi) is a publicly-traded Swedish specialty pharmaceutical company dedicated to rare diseases, hematology, immunology, and specialty care. With a market valuation of approximately $13.3 billion, Sobi has built a strong commercial portfolio including treatments for hemophilia, primary immunodeficiencies, and other rare conditions. The company combines in-house R&D capabilities with strategic partnerships and acquisitions to advance innovative therapies from development through commercialization.

Rare DiseasesHematologyImmunologyHemophiliaPrimary Immunodeficiencies

Technology Platform

Specialty biopharmaceutical platform focused on rare diseases with expertise in complex protein therapies, enzyme replacement treatments, and specialized manufacturing capabilities.

Pipeline

85
85 drugs in pipeline26 in Phase 3
DrugIndicationStageWatch
Recombinant coagulation factor (rFVIIIFc)Hemophilia AApproved
rFVIIIFcHemophilia A With InhibitorsApproved
AnakinraFamilial Mediterranean Fever (FMF )Approved
Efanesoctocog alfaHemophilia AApproved
Kepivance (Palifermin)Non-Hodgkin's LymphomaApproved

Funding History

1
IPOUndisclosedJun 15, 2005

FDA Approved Drugs

6
GAMIFANTBLANov 20, 2018
ORFADINNDAApr 22, 2016
KEPIVANCEBLADec 15, 2004

Opportunities

Significant growth potential in the expanding rare disease market with only 5% of rare diseases currently having approved treatments.
Strong commercial portfolio provides foundation for continued pipeline investment and potential strategic acquisitions.

Risk Factors

Regulatory approval uncertainties, competition from biosimilars, reimbursement challenges, and inherent complexities of rare disease development including small patient populations and clinical trial recruitment difficulties.

Competitive Landscape

Competes with specialized rare disease companies including Alexion/AstraZeneca, Shire/Takeda, BioMarin, and Sarepta Therapeutics. Differentiated through focused rare disease approach and established commercial infrastructure.